STOCK TITAN

Esperion to Participate in Upcoming May Investor Conferences

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary

Esperion (NASDAQ: ESPR) will participate in investor events in May, including JMP Securities’ Life Sciences Conference, Bank of America Securities’ Health Care Conference, and H.C. Wainwright’s BioConnect Investor Conference. Esperion focuses on developing medicines for cardiovascular and cardiometabolic diseases, aiming to improve outcomes for patients with high cholesterol.

Positive
  • None.
Negative
  • None.

ANN ARBOR, Mich., April 29, 2024 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that the company will be participating in the following webcasted investor events during the month of May, which can be found on our investor relations website.


JMP Securities’ Life Sciences Conference in New York on May 13, 2024, at 2:30 p.m. ET.

Bank of America Securities’ 2024 Health Care Conference in Las Vegas on May 15, 2024, at 3:00 p.m. PT / 6:00 p.m. ET.

H.C. Wainwright’s 2nd Annual BioConnect Investor Conference in New York on May 20, 2024, at 10:00 a.m. ET.

Live webcasts can be accessed on the investor and media section of the Esperion website. Access to the webcast replay will be available approximately two hours after the completion of the call and will be archived on the Company’s website for approximately 90 days.

Esperion Therapeutics
At Esperion, we discover, develop, and commercialize innovative medicines to help improve outcomes for patients with or at risk for cardiovascular and cardiometabolic diseases. The status quo is not meeting the health needs of millions of people with high cholesterol – that is why our team of passionate industry leaders is breaking through the barriers that prevent patients from reaching their goals. Providers are moving toward reducing LDL-cholesterol levels as low as possible, as soon as possible; we provide the next steps to help get patients there. Because when it comes to high cholesterol, getting to goal is not optional. It is our life’s work. For more information, visit esperion.com and esperionscience.com and follow us on X at twitter.com/EsperionInc.

Esperion Contact Information:
Investors:
investorrelations@esperion.com

Media:
Tiffany Aldrich
corporateteam@esperion.com
(616) 443-8438


FAQ

When will Esperion participate in the JMP Securities’ Life Sciences Conference?

Esperion will participate in the JMP Securities’ Life Sciences Conference on May 13, 2024, at 2:30 p.m. ET.

What is Esperion's focus in developing medicines?

Esperion focuses on developing medicines for cardiovascular and cardiometabolic diseases.

Where can the live webcasts of Esperion's investor events be accessed?

The live webcasts can be accessed on the investor and media section of Esperion's website.

How can one access the webcast replay of Esperion's events?

The webcast replay will be available on the Company's website approximately two hours after the completion of the call and will be archived for about 90 days.

Esperion Therapeutics, Inc.

NASDAQ:ESPR

ESPR Rankings

ESPR Latest News

ESPR Stock Data

490.70M
183.65M
0.45%
39.06%
10.77%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States of America
ANN ARBOR

About ESPR

esperion therapeutics, inc. is a pharmaceutical company focused on developing and commercializing first-in-class, oral, ldl-c lowering therapies for the treatment of patients with hypercholesterolemia. etc-1002, the company's lead product candidate, is an inhibitor of atp citrate lyase, a well-characterized enzyme on the cholesterol biosynthesis pathway; the same pathway that includes hmg-coa reductase, the enzyme target of statins. the company has successfully completed its phase 1 and phase 2 development programs for etc-1002, and plans to initiate its etc-1002 phase 3 development program by the end of 2015. for more information, please visit www.esperion.com.